TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$3.08 +0.03 (+0.98%) As of 09/5/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock About Medexus Pharmaceuticals Stock (TSE:MDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDP alerts:Sign Up Key Stats Today's RangeC$3.01▼C$3.1250-Day RangeC$2.61▼C$3.1752-Week RangeC$1.71▼C$5.56Volume20,200 shsAverage Volume71,499 shsMarket CapitalizationC$99.35 millionP/E Ratio154.00Dividend YieldN/APrice TargetC$5.49Consensus RatingBuy Company Overview Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action. Read More Medexus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreMDP MarketRank™: Medexus Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingBuy Consensus RatingMedexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Upside PotentialMedexus Pharmaceuticals has a consensus price target of C$5.49, representing about 78.2% upside from its current price of C$3.08.Amount of Analyst CoverageMedexus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Medexus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Medexus Pharmaceuticals is 154.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 278.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Medexus Pharmaceuticals is 154.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 76.29.Price to Book Value per Share RatioMedexus Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedexus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMedexus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDP. News and Social Media2.2 / 5News SentimentN/A News SentimentMedexus Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medexus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 0.60% of the stock of Medexus Pharmaceuticals is held by institutions.Read more about Medexus Pharmaceuticals' insider trading history. Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDP Stock News HeadlinesEarnings To Watch: Medexus Pharmaceuticals Inc (TSX:MDP) Reports Q1 2026 ResultAugust 14, 2025 | finance.yahoo.comMedexus Pharmaceuticals Inc. (MDP) Stock Price Today - WSJJuly 15, 2025 | wsj.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 7 at 2:00 AM | Banyan Hill Publishing (Ad)Medexus Pharmaceuticals Inc (TSX:MDP) Q4 2025: Everything You Need To Know Ahead Of EarningsJune 27, 2025 | finance.yahoo.comMedexus Pharmaceuticals Inc (TSX:MDP) Q4 2025 Earnings Report Preview: What To Look ForJune 26, 2025 | finance.yahoo.comShould We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?April 18, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDPJanuary 29, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - MDPJanuary 29, 2025 | ca.finance.yahoo.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$3.46 on January 1st, 2025. Since then, MDP stock has decreased by 11.0% and is now trading at C$3.08. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Price Target for Medexus PharmaceuticalsC$5.49 High Price TargetC$8.25 Low Price TargetC$3.45 Potential Upside/Downside+78.2%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)C$0.02 Trailing P/E Ratio154.00 Forward P/E Ratio18.86 P/E GrowthN/ANet IncomeC$3.26 million Net Margins3.25% Pretax MarginN/A Return on Equity11.07% Return on Assets4.89% Debt Debt-to-Equity Ratio120.58 Current Ratio1.01 Quick RatioN/A Sales & Book Value Annual SalesC$105.66 million Price / Sales0.94 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.35 per share Price / Book2.28Miscellaneous Outstanding Shares32,258,000Free FloatN/AMarket CapC$99.35 million OptionableNot Optionable Beta2.55 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (TSE:MDP) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.